Pfizer: Q4 Earnings Insights

Shares of Pfizer PFE fell 0.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 23.64% over the past year to $0.42, which missed the estimate of $0.48.

Revenue of $11,684,000,000 declined by 7.91% from the same period last year, which beat the estimate of $11,430,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $3.10 and $3.20.

The upcoming fiscal year's revenue expected to be between $59,400,000,000 and $61,400,000,000.

Conference Call Details

Date: Feb 02, 2021

Time: 10:00 AM

ET Webcast URL: https://pfizerevents.webex.com/mw3300/mywebex/default.do?nomenu=true&siteurl=pfizerevents&service=6&rnd=0.1556829967021055&main_url=https%3A%2F%2Fpfizerevents.webex.com%2Fec3300%2Feventcenter%2Fevent%2FeventAction.do%3FtheAction%3Ddetail%26%26%26EMK%3D4832534b00000004776dca4923662b6863856d9f6348591cdd902c67d50d713cac36959dbc98cfe2%26siteurl%3Dpfizerevents%26confViewID%3D180721088377923754%26encryptTicket%3DSDJTSwAAAARh6wUs-ZAUi1RvLkNH5JLhYWUUrcY45vP9arPCagzoSw2%26

Price Action

Company's 52-week high was at $43.08

Company's 52-week low was at $27.88

Price action over last quarter: Up 6.37%

Company Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.